Gynecological Cancer Drugs Market Expected to Reach $21.8 Billion by 2030—Allied Market Research

According to a new report published by Allied Market Research, titled, “Gynecological Cancer Drugs Market," TheGynecological Cancer Drugs Market Size was valued at $11.6 billion in 2020 and is estimated to reach $21.8 billion by 2030, growing at a CAGR of 6.5% from 2021 to 2030.

Cancer progresses when normal body cells transform into abnormal cells and continue to grow in an uncontrolled manner. It is named after the body part in which it originates, so gynecological cancer refers to a group of cancers that affect the reproductive organs of a female. Gynecological cancers include cancer in the uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle &tissue supporting the uterus.

The key factors that drive the growth of the Gynecological Cancer Drugs Industry are an increase in funding of R&D in the activities of gynecological cancer drugs along with rising in the prevalence of cancer. In addition, the favorable government regulations for therapy are further going to boost the Gynecological Cancer Drugs Market Growth during the forecast period. However, the high cost involved in gene therapy along with unwanted immune responses is likely to hamper the growth of the gynecological cancer drugs market during the forecast period. Conversely, advancements in cancer drug research and the advent of personalized medicine approach are expected to provide numerous opportunities for market growth during the forecast period.

By indication, the indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. The cervical cancer segment dominated the market in 2020 and is expected to remain dominant during the forecast period, owing to a surge in the incidence of cervical cancer among all the gynecological cancers.

Depending on therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The targeted therapy segment dominated the market in 2020 and is expected to remain dominant during the forecast period, owing to the increased benefits of targeted therapy over chemotherapy.

The Gynecological Cancer Drugs Industry is segmented into therapeutic modality, indication, and region. By therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

By region, Gynecological Cancer Drugs Market Analysis is done across North America, Europe, Asia-Pacific, and LAMEA. North America has the highest Gynecological Cancer Drugs Market Share, in 2020. Owing to significant investments in research and advancements in technology, the Asia-Pacific market is estimated to reach $5654.88 million at a significant CAGR of 7.1% in 2030. The presence of a large population base, government initiatives to improve healthcare infrastructure, and an increase in healthcare expenditure are the key driving factors that boost the gynecological cancer drugs market in the region.

KEY FINDINGS OF THE STUDY

• On the basis of therapeutic modality, the targeted therapy segment dominated the market in 2020 and is expected to continue this trend during the forecast period.
• On the basis of indication, the cervical cancer segment dominated the market in 2020 and is expected to continue this trend during the forecast period.
• Region-wise, North America garnered the largest revenue share in 2020. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.